dual PD-1 checkpoint inhibitor/BTLA checkpoint inhibitor (Xencor)

N/A

Report date: 2025/01/26 18:33:44

Base Information

Drug Namedual PD-1 checkpoint inhibitor/BTLA checkpoint inhibitor (Xencor)

Drug Alias NamePD-1/BTLA bispecific mAbs (Xencor)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionB- and T-lymphocyte attenuator blockersProgrammed cell death protein 1 blockers

TargetsB- and T-lymphocyte attenuatorProgrammed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A